Abstract
Diverticula are outpouchings of the intestinal wall and are common anatomical alterations detected in the human colon. Colonic diverticulosis (the presence of diverticula in the colon; referred to as diverticulosis) remains asymptomatic in most individuals but ~25% of individuals will develop symptomatic diverticulosis, termed colonic diverticular disease (also known as diverticular disease). Diverticular disease can range in severity from symptomatic uncomplicated diverticular disease (SUDD) to symptomatic disease with complications such as acute diverticulitis or diverticular haemorrhage. Since the early 2000s, a greater understanding of the pathophysiology of diverticulosis and diverticular disease, which encompasses genetic alterations, chronic low-grade inflammation and gut dysbiosis, has led to improvements in diagnosis and management. Diagnosis of diverticular disease relies on imaging approaches, such as ultrasonography, CT and MRI, as biomarkers alone are insufficient to establish a diagnosis despite their role in determining disease severity and progression as well as in differential diagnosis. Treatments for diverticular disease include dietary fibre, pharmacological treatments such as antibiotics (rifaximin), anti-inflammatory drugs (mesalazine) and probiotics, alone or in combination, and eventually surgery. Despite being effective in treating primary disease, their effectiveness in primary and secondary prevention of complications is still uncertain.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 1 digital issues and online access to articles
$119.00 per year
only $119.00 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
17 June 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
29 April 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
References
Tursi, A. Diverticulosis today: unfashionable and still under-researched. Therap. Adv. Gastroenterol. 9, 213–228 (2015).
Schieffer, K. M., Kline, B. P., Yochum, G. S. & Koltun, W. A. Pathophysiology of diverticular disease. Expert Rev. Gastroenterol. Hepatol. 12, 683–692 (2018).
Tursi, A., Papa, A. & Danese, S. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Aliment. Pharmacol. Ther. 42, 664–684 (2015).
Cuomo, R., Cargiolli, M., Cassarano, S., Carabotti, M. & Annibale, B. Treatment of diverticular disease, targeting symptoms or underlying mechanisms. Curr. Opin. Pharmacol. 43, 124–131 (2018).
Sato, H. et al. Esophageal diverticulum: new perspectives in the era of minimally invasive endoscopic treatment. World J. Gastroenterol. 25, 1457–1464 (2019).
Shah, J., Patel, K., Sunkara, T., Papafragkakis, C. & Shahidullah, A. Gastric diverticulum: a comprehensive review. Inflamm. Intest. Dis. 3, 161–166 (2019).
Rangan, V. & Lamont, J. T. Small bowel diverticulosis: pathogenesis, clinical management, and new concepts. Curr. Gastroenterol. Rep. 22, 4 (2020).
Lanas, A., Abad-Baroja, D. & Lanas-Gimeno, A. Progress and challenges in the management of diverticular disease: which treatment? Therap. Adv. Gastroenterol. 11, 175628481878905 (2018).
Everhart, J. E. & Ruhl, C. E. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 136, 741–754 (2009).
Peery, A. F. et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 149, 1731–1741.e3 (2015).
Yamamichi, N. et al. Trend and risk factors of diverticulosis in japan: age, gender, and lifestyle/metabolic-related factors may cooperatively affect on the colorectal diverticula formation. PLoS One 10, e0123688 (2015). This study assesses the characteristics and the risk factors for diverticulosis in a Far East nation.
Song, J. H. et al. Clinical characteristics of colonic diverticulosis in Korea: a prospective study. Korean J. Intern. Med. 25, 140–146 (2010).
Golder, M. et al. Demographic determinants of risk, colon distribution and density scores of diverticular disease. World J. Gastroenterol. 17, 1009–1017 (2011).
Peery, A. F. Colonic diverticula and diverticular disease: 10 facts clinicians should know. N. C. Med. J. 77, 220–222 (2016).
Shahedi, K. et al. Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin. Gastroenterol. Hepatol. 11, 1609–1613 (2013). This is a long-term study showing that the risk of acute diverticulitis occurrence in incidental diverticulosis is lower than expected.
Faucheron, J.-L., Roblin, X., Bichard, P. & Heluwaert, F. The prevalence of right-sided colonic diverticulosis and diverticular haemorrhage. Colorectal Dis. 15, e266–e270 (2013).
Peery, A. F. & Sandler, R. S. Diverticular disease: reconsidering conventional wisdom. Clin. Gastroenterol. Hepatol. 11, 1532–1537 (2013).
Gralnek, I. M., Neeman, Z. & Strate, L. L. Acute lower gastrointestinal bleeding. N. Engl. J. Med. 376, 1054–1063 (2017).
Delvaux, M. Diverticular disease of the colon in Europe: epidemiology, impact on citizen health and prevention. Aliment. Pharmacol. Ther. 18, 71–74 (2003).
Jeyarajah, S. et al. Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions. Aliment. Pharmacol. Ther. 30, 1171–1182 (2009).
Binda, G. A. et al. Trends in hospital admission for acute diverticulitis in Italy from 2008 to 2015. Tech. Coloproctol. 22, 597–604 (2018).
Strate, L. L. & Morris, A. M. Epidemiology, pathophysiology, and treatment of diverticulitis. Gastroenterology 156, 1282–1298.e1 (2019).
Böhm, S. K. & Kruis, W. Lifestyle and other risk factors for diverticulitis. Minerva Gastroenterol. Dietol. 63, 110–118 (2017).
Jovani, M. et al. Menopausal hormone therapy and risk of diverticulitis. Am. J. Gastroenterol. 114, 315–321 (2019).
Hjern, F., Johansson, C., Mellgren, A., Baxter, N. N. & Hjern, A. Diverticular disease and migration - the influence of acculturation to a Western lifestyle on diverticular disease. Aliment. Pharmacol. Ther. 23, 797–805 (2006). This is an epidemiological study assessing the role of changing lifestyle on the risk of diverticular disease occurrence.
Crowe, F. L., Appleby, P. N., Allen, N. E. & Key, T. J. Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): prospective study of British vegetarians and non-vegetarians. BMJ 343, d4131 (2011). This is a large study that found fibre is a significant predictive factor for occurrence of diverticular disease.
Strate, L. L., Liu, Y. L., Huang, E. S., Giovannucci, E. L. & Chan, A. T. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology 140, 1427–1433 (2011).
Liu, P.-H. et al. Adherence to a healthy lifestyle is associated with a lower risk of diverticulitis among men. Am. J. Gastroenterol. 112, 1868–1876 (2017).
Wess, L., Eastwood, M. A., Edwards, C. A., Busuttil, A. & Miller, A. Collagen alteration in an animal model of colonic diverticulosis. Gut 38, 701–706 (1996).
Wedel, T., Barrenschee, M., Lange, C., Cossais, F. & Böttner, M. Morphologic basis for developing diverticular disease, diverticulitis, and diverticular bleeding. Visc. Med. 31, 76–82 (2015).
Cao, Y. et al. Meat intake and risk of diverticulitis among men. Gut 67, 466–472 (2017).
Ma, W. et al. Association between obesity and weight change and risk of diverticulitis in women. Gastroenterology 155, 58–66.e4 (2018).
Strate, L. L., Liu, Y. L., Aldoori, W. H., Syngal, S. & Giovannucci, E. L. Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology 136, 115–122.e1 (2009).
Hjern, F., Wolk, A. & Håkansson, N. Smoking and the risk of diverticular disease in women. Br. J. Surg. 98, 997–1002 (2011).
Strate, L. L., Liu, Y. L., Aldoori, W. H. & Giovannucci, E. L. Physical activity decreases diverticular complications. Am. J. Gastroenterol. 104, 1221–1230 (2009).
Ridker, P. M., Buring, J. E., Cook, N. R. & Rifai, N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 107, 391–397 (2003).
Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E. & Ridker, P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327–334 (2001).
Ma, W. et al. Association between inflammatory diets, circulating markers of inflammation, and risk of diverticulitis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2019.11.011 (2019).
Humes, D. J. et al. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol. Motil. 24, 318-e163 (2012).
Tursi, A. et al. Faecal calprotectin in colonic diverticular disease: a case–control study. Int. J. Colorectal Dis. 24, 49–55 (2008).
Peery, A. F. et al. Colonic diverticula are not associated with mucosal inflammation or chronic gastrointestinal symptoms. Clin. Gastroenterol. Hepatol. 16, 884–891.e1 (2018).
Järbrink-Sehgal, M. E. et al. Diverticulosis, symptoms and colonic inflammation: a population-based colonoscopy study. Am. J. Gastroenterol. 114, 500–510 (2019).
Lahat, A. et al. Prolonged recurrent abdominal pain is associated with ongoing underlying mucosal inflammation in patients who had an episode of acute complicated diverticulitis. J. Clin. Gastroenterol. 53, e178–e185 (2019).
Tursi, A. et al. Detection of endoscopic and histological inflammation after an attack of colonic diverticulitis is associated with higher diverticulitis recurrence. J. Gastrointestin. Liver Dis. 22, 13–19 (2013).
Lopez-Garcia, E. et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am. J. Clin. Nutr. 80, 1029–1035 (2004).
Turnbaugh, P. J., Bäckhed, F., Fulton, L. & Gordon, J. I. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213–223 (2008).
Turnbaugh, P. J. & Gordon, J. I. The core gut microbiome, energy balance and obesity. J. Physiol. 587, 4153–4158 (2009).
Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness. Nature 500, 585–588 (2013).
De Filippis, F. et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut 65, 1812–1821 (2015).
Makki, K., Deehan, E. C., Walter, J. & Bäckhed, F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe 23, 705–715 (2018).
Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Bäckhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165, 1332–1345 (2016).
Krokowicz, L. et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis — a prospective randomized study. Int. J. Colorectal Dis. 29, 387–393 (2013).
Hullar, M. A., Sandstrom, R., Lampe, J. W. & Strate, L. L. The fecal microbiome differentiates patients with a history of diverticulitis vs those with uncomplicated diverticulosis. Gastroenterology 152, S624 (2017).
Daniels, L. et al. Fecal microbiome analysis as a diagnostic test for diverticulitis. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1927–1936 (2014). This is the first study to demonstrate that diverticulitis is associated with significant changes in faecal microbiome.
Barbara, G. et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut 66, 1252–1261 (2016).
Kvasnovsky, C. L. et al. Clinical and symptom scores are significantly correlated with fecal microbiota features in patients with symptomatic uncomplicated diverticular disease. Eur. J. Gastroenterol. Hepatol. 30, 107–112 (2018). This is the first study that found that changes in microbiota features are linked to symptom expression in patients with SUDD.
Tursi, A. et al. Assessment of fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon. J. Clin. Gastroenterol. 50, S9–S12 (2016).
Jones, R. B. et al. An aberrant microbiota is not strongly associated with incidental colonic diverticulosis. Sci. Rep. 8, 4951 (2018).
Painter, N. S. Diverticular disease of the colon — a disease of western civilisation. Dis. Mon. 16, 1–57 (1970).
Maguire, L. H. et al. Genome-wide association analyses identify 39 new susceptibility loci for diverticular disease. Nat. Genet. 50, 1359–1365 (2018).
Rosemar, A., Ivarsson, M.-L., Börjesson, L. & Holmdahl, L. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease. Scand. J. Gastroenterol. 42, 215–220 (2007).
Wedel, T. et al. Diverticular disease is associated with an enteric neuropathy as revealed by morphometric analysis. Neurogastroenterol. Motil. 22, 407-e94 (2010).
Bassotti, G. et al. Alterations in colonic motility and relationship to pain in colonic diverticulosis. Clin. Gastroenterol. Hepatol. 3, 248–253 (2005).
Böttner, M. et al. The GDNF system is altered in diverticular disease – implications for pathogenesis. PLoS One 8, e66290 (2013).
Golder, M. et al. Smooth muscle cholinergic denervation hypersensitivity in diverticular disease. Lancet 361, 1945–1951 (2003).
Bassotti, G. Interstitial cells of Cajal, enteric nerves, and glial cells in colonic diverticular disease. J. Clin. Pathol. 58, 973–977 (2005).
Clemens, C. H. M. Colorectal visceral perception in diverticular disease. Gut 53, 717–722 (2004).
Barbaro, M. R. et al. Nerve fiber overgrowth in patients with symptomatic diverticular disease. Neurogastroenterol. Motil. 31, e13575 (2019).
Bode, M. K., J. K., T. & Mäk., J. Type I and III collagens in human colon cancer and diverticulosis. Scand. J. Gastroenterol. 35, 747–752 (2000).
Beighton, P. H., Murdoch, J. L. & Votteler, T. Gastrointestinal complications of the Ehlers-Danlos syndrome. Gut 10, 1004–1008 (1969).
Stagi, S., Lapi, E., Chiarelli, F. & de Martino, M. Incidence of diverticular disease and complicated diverticular disease in young patients with Williams syndrome. Pediatric Surg. Int. 26, 943–944 (2010).
Suster, S. M. Diverticulosis coli in association with Marfan’s syndrome. Arch. Intern. Med. 144, 203 (1984).
Granlund, J. et al. The genetic influence on diverticular disease–a twin study. Aliment. Pharmacol. Ther. 35, 1103–1107 (2012).
Strate, L. L. et al. Heritability and familial aggregation of diverticular disease: a population-based study of twins and siblings. Gastroenterology 144, 736–742.e1 (2013).
Reichert, M. C. et al. A variant of COL3A1 (rs3134646) is associated with risk of developing diverticulosis in white men. Dis. Colon Rectum 61, 604–611 (2018).
Connelly, T. M. et al. The TNFSF15 gene single nucleotide polymorphism rs7848647 is associated with surgical diverticulitis. Ann. Surg. 259, 1132–1137 (2014).
Beasley, W. D., Beynon, J., Jenkins, G. J. S. & Parry, J. M. Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case–control disease association study. Int. J. Colorectal Dis. 23, 375–381 (2008).
Coble, J. L. et al. Identification of a rare LAMB4 variant associated with familial diverticulitis through exome sequencing. Hum. Mol. Genet. 26, 3212–3220 (2017).
Camilleri, M., Sandler, R. S. & Peery, A. F. Etiopathogenetic mechanisms in diverticular disease of the colon. Cell. Mol. Gastroenterol. Hepatol. 9, 15–32 (2020).
Sigurdsson, S. et al. Sequence variants in ARHGAP15, COLQ and FAM155A associate with diverticular disease and diverticulitis. Nat. Commun. 8, 15789 (2017).
Schafmayer, C. et al. Genome-wide association analysis of diverticular disease points towards neuromuscular, connective tissue and epithelial pathomechanisms. Gut 68, 854–865 (2019). This is a large study assessing the role of several genes coding for neuromuscular, connective tissue and epithelial functions in predisposing to the occurrence of diverticular disease.
Kruis, W., Germer, C.-T. & Leifeld, L. Diverticular disease: guidelines of the German Society for Gastroenterology, Digestive and Metabolic Diseases and the German Society for General and Visceral Surgery. Digestion 90, 190–207 (2014).
Toorenvliet, B. R., Bakker, R. F. R., Breslau, P. J., Merkus, J. W. S. & Hamming, J. F. Colonic diverticulitis: a prospective analysis of diagnostic accuracy and clinical decision-making. Colorectal Dis. 12, 179–186 (2010).
Farag Soliman, M. et al. Primary diagnostics of acute diverticulitis of the sigmoid. Ultraschall Med. 25, 342–347 (2004).
Andeweg, C. S., Knobben, L., Hendriks, J. C. M., Bleichrodt, R. P. & van Goor, H. How to diagnose acute left-sided colonic diverticulitis. Ann. Surg. 253, 940–946 (2011).
Niikura, R., Nagata, N., Shimbo, T., Akiyama, J. & Uemura, N. Colonoscopy can miss diverticula of the left colon identified by barium enema. World J. Gastroenterol. 19, 2362–2367 (2013).
Andeweg, C. S. et al. Toward an evidence-based step-up approach in diagnosing diverticulitis. Scand. J. Gastroenterol. 49, 775–784 (2014).
Bor, R., Fábián, A. & Szepes, Z. Role of ultrasound in colorectal diseases. World J. Gastroenterol. 22, 9477–9487 (2016).
Lembcke, B. J., Strobel, D., Dirks, K., Becker, D. & Menzel, J. Statement of the Section Internal Medicine of the DEGUM – ultrasound obtains pole position for clinical imaging in acute diverticulitis. Ultraschall Med. 36, 191–195 (2015).
Swanson, S. M. & Strate, L. L. Acute colonic diverticulitis. Ann. Intern. Med. 168, ITC65–ITC80 (2018).
Min, J. H. et al. The value of initial sonography compared to supplementary CT for diagnosing right-sided colonic diverticulitis. Jpn. J. Radiol. 35, 358–365 (2017).
Schwerk, W. B., Schwarz, S. & Rothmund, M. Sonography in acute colonic diverticulitis. Dis. Colon Rectum 35, 1077–1084 (1992).
Puylaert, J. B. C. M. Ultrasound of colon diverticulitis. Digestive Dis. 30, 56–59 (2012).
Nielsen, K. et al. The limited role of ultrasound in the diagnostic process of colonic diverticulitis. World J. Surg. 38, 1814–1818 (2014).
Heverhagen, J. T., Sitter, H., Zielke, A. & Klose, K. J. Prospective evaluation of the value of magnetic resonance imaging in suspected acute sigmoid diverticulitis. Dis. Colon Rectum 51, 1810–1815 (2008).
Hollerweger, A., Macheiner, P., Rettenbacher, T., Brunner, W. & Gritzmann, N. Colonic diverticulitis: diagnostic value and appearance of inflamed diverticula–sonographic evaluation. Eur. Radiol. 11, 1956–1963 (2001).
Liljegren, G., Chabok, A., Wickbom, M., Smedh, K. & Nilsson, K. Acute colonic diverticulitis: a systematic review of diagnostic accuracy. Colorectal Dis. 9, 480–488 (2007).
Dickerson, E. C. et al. Recurrence of colonic diverticulitis: identifying predictive CT findings — retrospective cohort study. Radiology 285, 850–858 (2017).
Ünlü, Ç. et al. Inter-observer reliability of computed tomographic classifications of diverticulitis. Colorectal Dis. 16, O212–O219 (2014).
Ripollés, T., Martínez-Pérez, M. J., Gómez Valencia, D. P., Vizuete, J. & Martín, G. Sigmoid stenosis caused by diverticulitis vs. carcinoma: usefulness of sonographic features for their differentiation in the emergency setting. Abdom. Imaging 40, 2219–2231 (2015).
Bar-Meir, S., Lahat, A. & Melzer, E. Role of endoscopy in patients with diverticular disease. Digestive Dis. 30, 60–63 (2012).
Lahat, A., Yanai, H., Sakhnini, E., Menachem, Y. & Bar-Meir, S. Role of colonoscopy in patients with persistent acute diverticulitis. World J. Gastroenterol. 14, 2763–2766 (2008).
Mohammed Ilyas, M. I. & Szilagy, E. Management of diverticular bleeding: evaluation, stabilization, intervention, and recurrence of bleeding and indications for resection after control of bleeding. Clin. Colon Rectal Surg. 31, 243–250 (2018).
Strate, L. L. & Gralnek, I. M. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am. J. Gastroenterol. 111, 459–474 (2016).
Jensen, D. M., Machicado, G. A., Jutabha, R. & Kovacs, T. O. G. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. N. Engl. J. Med. 342, 78–82 (2000).
Navaneethan, U., Njei, B., Venkatesh, P. G. K. & Sanaka, M. R. Timing of colonoscopy and outcomes in patients with lower GI bleeding: a nationwide population-based study. Gastrointest. Endosc. 79, 297–306.e12 (2014).
Pasha, S. F. et al. The role of endoscopy in the patient with lower GI bleeding. Gastrointest. Endosc. 79, 875–885 (2014).
Nagata, N. et al. Guidelines for colonic diverticular bleeding and colonic diverticulitis: Japan Gastroenterological Association. Digestion 99, 1–26 (2019).
Parkes, B. M., Obeid, F. N., Sorensen, V. J., Horst, H. M. & Fath, J. J. The management of massive lower gastrointestinal bleeding. Am. Surg. 59, 676–678 (1993).
Meyer, J. et al. Risk of colorectal cancer in patients with acute diverticulitis: a systematic review and meta-analysis of observational studies. Clin. Gastroenterol. Hepatol. 17, 1448–1456.e17 (2019).
Mounce, L. T. A., Price, S., Valderas, J. M. & Hamilton, W. Comorbid conditions delay diagnosis of colorectal cancer: a cohort study using electronic primary care records. Br. J. Cancer 116, 1536–1543 (2017).
Feingold, D. et al. Practice parameters for the treatment of sigmoid diverticulitis. Dis. Colon Rectum 57, 284–294 (2014).
Sharma, P. V., Eglinton, T., Hider, P. & Frizelle, F. Systematic review and meta-analysis of the role of routine colonic evaluation after radiologically confirmed acute diverticulitis. Ann. Surg. 259, 263–272 (2014).
Andrade, P., Ribeiro, A., Ramalho, R., Lopes, S. & Macedo, G. Routine colonoscopy after acute uncomplicated diverticulitis – challenging a putative indication. Dig. Surg. 34, 197–202 (2016).
Rottier, S. J. et al. Meta-analysis of the role of colonoscopy after an episode of left-sided acute diverticulitis. Br. J. Surg. 106, 988–997 (2019).
Kechagias, A. et al. Index C-reactive protein predicts increased severity in acute sigmoid diverticulitis. Ther. Clin. Risk Manag. 14, 1847–1853 (2018).
Tursi, A. Biomarkers in diverticular diseases of the colon. Dig. Dis. 30, 12–18 (2012).
Nemakayala, D. R. & Cash, B. D. Excluding irritable bowel syndrome in the inflammatory bowel disease patient. Curr. Opin. Gastroenterol. 35, 58–62 (2019).
Waugh, N. et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol. Assess 17, xv–xix (2013).
Tursi, A. A critical appraisal of advances in the diagnosis of diverticular disease. Expert Rev. Gastroenterol. Hepatol. 12, 791–796 (2018).
Cuomo, R. et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur. J. Clin. Invest. 43, 1147–1155 (2013).
Tursi, A., Elisei, W., Picchio, M., Giorgetti, G. M. & Brandimarte, G. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon. J. Clin. Gastroenterol. 49, 218–221 (2015). This is a clinical study showing how clinical characteristics, together with faecal calprotectin expression, might be useful in differentiating SUDD from IBS.
Tan, W. J. et al. Systematic review and meta-analysis of the use of serum procalcitonin levels to predict intra-abdominal infections after colorectal surgery. Int. J. Colorectal Dis. 33, 171–180 (2018).
Sager, R., Kutz, A., Mueller, B. & Schuetz, P. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 15, 15 (2017).
Woodhead, M. et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin. Microbiol. Infect. 17, E1–E59 (2011).
Schuetz, P. et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections. Cochrane Database Syst. Rev. 4, CD007498 (2009).
Jeger, V. et al. Correction to: Jeger V, et al. Is there a role for procalcitonin in differentiating uncomplicated and complicated diverticulitis in order to reduce antibiotic therapy? Swiss Med. Wkly 148, w14673 (2018).
Tursi, A., Elisei, W., Picchio, M., Di Mario, F. & Brandimarte, G. Serum levels of vitamin D are associated with the severity of the endoscopic appearance of diverticular disease of the colon according to DICA classification. J. Gastrointestin. Liver Dis. 25, 567–568 (2016).
Tursi, A. et al. Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. Dig. Dis. 33, 68–76 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02758860 (2018).
Tursi, A. et al. Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: an international study. United European Gastroenterol. J. 4, 604–613 (2016).
Tursi, A. et al. P.02.12 Predictive value of the “DICA” endoscopic classification on the outcome of diverticular disease of the colon: a 1-year analysis from the international, multicenter, prospective study. Digestive Liver Dis. 51, e152–e153 (2019). This paper is the first endoscopic classification for diverticulosis and diverticular disease that also has a value in predicting the outcome of the disease.
Laméris, W. et al. Graded compression ultrasonography and computed tomography in acute colonic diverticulitis: meta-analysis of test accuracy. Eur. Radiol. 18, 2498–2511 (2008).
Hinchey, E. J., Schaal, P. G. & Richards, G. K. Treatment of perforated diverticular disease of the colon. Adv. Surg. 12, 85–109 (1978).
Wasvary, H., Turfah, F., Kadro, O. & Beauregard, W. Same hospitalization resection for acute diverticulitis. Am. Surg. 65, 632–635; discussion 636 (1999).
Painter, N. S. & Burkitt, D. P. Diverticular disease of the colon: a deficiency disease of Western civilization. BMJ 2, 450–454 (1971).
Strate, L. L., Modi, R., Cohen, E. & Spiegel, B. M. R. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am. J. Gastroenterol. 107, 1486–1493 (2012).
Scarpignato, C., Barbara, G., Lanas, A. & Strate, L. L. Management of colonic diverticular disease in the third millennium: highlights from a symposium held during the United European Gastroenterology Week 2017. Ther. Adv. Gastroenterol. 11, 1756284818771305 (2018).
Comparato, G. et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig. Dis. 25, 252–259 (2007).
Carabotti, M., Annibale, B., Severi, C. & Lahner, E. Role of fiber in symptomatic uncomplicated diverticular disease: a systematic review. Nutrients 9, 161 (2017).
Papi, C., Ciaco, A., Koch, M. & Capurso, L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 9, 33–39 (1995). This is a controlled double-blind study showing the efficacy and safety of cyclic treatment with rifaximin versus placebo in controlling symptoms in SUDD.
Schieffer, K. M. et al. The microbial ecosystem distinguishes chronically diseased tissue from adjacent tissue in the sigmoid colon of chronic, recurrent diverticulitis patients. Sci. Rep. 7, 8467 (2017).
Corazza, G. R., Di Stefano, M. & Scarpignato, C. Treatment of functional bowel disorders: is there room for antibiotics? Digestion 73, 38–46 (2006).
Kurpad, A. V. & Shetty, P. S. Effects of antimicrobial therapy on faecal bulking. Gut 27, 55–58 (1986).
Frieri, G., Pimpo, M. T. & Scarpignato, C. Management of colonic diverticular disease. Digestion 73, 58–66 (2006).
Latella, G. & Scarpignato, C. Rifaximin in the management of colonic diverticular disease. Expert Rev. Gastroenterol. Hepatol. 3, 585–598 (2009).
Kasturi, K. S., Mummadi, R. R. & Jaganmohan, S. Cyclical rifaximin for symptomatic, uncomplicated diverticular disease: a meta-analysis [abstract M1695]. Gastroenterology 134, A-399 (2008).
Bianchi, M. et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment. Pharmacol. Ther. 33, 902–910 (2011).
Scarpignato, C. & Pelosini, I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51, 36–66 (2005).
Ponziani, F. R., Zocco, M. A., D’Aversa, F., Pompili, M. & Gasbarrini, A. Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation. World J. Gastroenterol. 23, 4491–4499 (2017).
Gatta, L. & Scarpignato, C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment. Pharmacol. Ther. 45, 604–616 (2017).
Scarpignato, C. & Gatta, L. Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth. Aliment. Pharmacol. Ther. 38, 1409–1410 (2013).
Moniuszko, A. & Rydzewska, G. The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a “real-life” study. Gastroenterol. Rev. 2, 145–151 (2017).
Stallinger, S., Eller, N. & Högenauer, C. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease. Wien. Klin. Wochenschr. 126, 9–14 (2013).
Copaci, I., Constantinescu, G., Miha˘ila˘, M., Micu, L. & Franculescu-Bertea, A. Efficacy of rifaximin-α vs dietary fiber on the evolution of uncomplicated colonic diverticular disease. Surg. Gastroenterol. Oncol. 24, 233–240 (2019).
Di Mario, F. et al. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. J. Investig. Med. 67, 767–770 (2018).
Lauritano, E. C. et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am. J. Gastroenterol. 103, 2031–2035 (2008).
Charúa-Guindic, L. et al. Gastroenterology diagnosis and treatment guidelines of diverticular disease of the colon. Treatment [Spanish]. Rev. Gastroenterol. Mex. 73, 261–264 (2008).
Andersen, J. C. et al. Danish national guidelines for treatment of diverticular disease. Dan. Med. J. 59, C4453 (2012).
Cuomo, R. et al. Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterol. J. 2, 413–442 (2014).
Binda, G. A. et al. Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines. Tech. Coloproctol. 19, 615–626 (2015).
Pietrzak, A. et al. Polish interdisciplinary consensus on diagnostics and treatment of colonic diverticulosis (2015). Pol. Przegl. Chir. 87, 203–220 (2015).
Trifan, A. et al. Diagnosis and treatment of colonic diverticular disease: position paper of the Romanian Society of Gastroenterology and Hepatology. J. Gastrointestin. Liver Dis. 27, 449–457 (2018).
Cuomo, R., Barbara, G. & Annibale, B. Rifaximin and diverticular disease: position paper of the Italian Society of Gastroenterology (SIGE). Dig. Liver Dis. 49, 595–603 (2017).
Viscomi, G. C. et al. Crystal forms of rifaximin and their effect on pharmaceutical properties. CrystEngComm 10, 1074–1081 (2008).
Blandizzi, C., Viscomi, G. C., Marzo, A. & Scarpignato, C. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol. Res. 85, 39–44 (2014).
Dadgostar, P. Antimicrobial resistance: implications and costs. Infect. Drug Resist. 12, 3903–3910 (2019).
Cole, K. A., Rivard, K. R. & Dumkow, L. E. Antimicrobial stewardship interventions to combat antibiotic resistance: an update on targeted strategies. Curr. Infect. Dis. Rep. 21, 33 (2019).
Zuccaro, V. et al. Antibiotic stewardship and empirical antibiotic treatment: how can they get along? Dig. Liver Dis. 49, 579–584 (2017).
Ponziani, F. R. et al. Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. Expert Opin. Drug Saf. 15, 983–991 (2016).
Pimentel, M. et al. Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity. Dig. Dis. Sci. 62, 2455–2463 (2017).
Barbara, G., Cremon, C., Barbaro, M. R., Bellacosa, L. & Stanghellini, V. Treatment of diverticular disease with aminosalicylates: the evidence. J. Clin. Gastroenterol. 50, S60–S63 (2016).
Kruis, W. et al. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo-controlled study. Aliment. Pharmacol. Ther. 37, 680–690 (2013).
Tursi, A. et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double-blind, randomised, placebo-controlled study. Aliment. Pharmacol. Ther. 38, 741–751 (2013). This study is a controlled double-blind study showing the efficacy and safety of cyclic treatment with mesalazine, with or without probiotics, versus placebo in controlling symptoms in SUDD and in preventing acute diverticulitis in patients with SUDD.
Picchio, M. et al. Mesalazine for the treatment of symptomatic uncomplicated diverticular disease of the colon and for primary prevention of diverticulitis. J. Clin. Gastroenterol. 50, S64–S69 (2016).
Scarpignato, C., Bertelé, A. & Tursi, A. Probiotics for the treatment of symptomatic uncomplicated diverticular disease. J. Clin. Gastroenterol. 50, S70–S73 (2016).
Lahner, E. et al. Probiotics in the treatment of diverticular disease. A systematic review. J. Gastrointestin. Liver Dis. 25, 79–86 (2016).
Salem, T. A., Molloy, R. G. & O’Dwyer, P. J. Prospective, five-year follow-up study of patients with symptomatic uncomplicated diverticular disease. Dis. Colon Rectum 50, 1460–1464 (2007).
Picchio, M., Elisei, W. & Tursi, A. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials. J. Gastrointestin. Liver Dis. 27, 291–297 (2018).
Jacobs, D. O. Diverticulitis. N. Engl. J. Med. 357, 2057–2066 (2007).
Young-Fadok, T. M. Diverticulitis. N. Engl. J. Med. 379, 1635–1642 (2018).
Slim, K., Joris, J. & Beyer-Berjot, L. The end of antibiotics in the management of uncomplicated acute diverticulitis. J. Visc. Surg. 156, 373–375 (2019).
Rottier, S. J. et al. Complicated disease course in initially computed tomography-proven uncomplicated acute diverticulitis. Surg. Infect. 20, 453–459 (2019).
Bolkenstein, H. E. et al. Long-term outcome of surgery versus conservative management for recurrent and ongoing complaints after an episode of diverticulitis: 5-year follow-up results of a multicenter randomized controlled trial (DIRECT-trial). Ann. Surg. 269, 612–620 (2019).
Jaung, R. et al. Uncomplicated acute diverticulitis: identifying risk factors for severe outcomes. World J. Surg. 41, 2258–2265 (2017).
Sánchez-Velázquez, P., Grande, L. & Pera, M. Outpatient treatment of uncomplicated diverticulitis. Eur. J. Gastroenterol. Hepatol. 28, 622–627 (2016).
Balasubramanian, I. et al. Out-patient management of mild or uncomplicated diverticulitis: a systematic review. Digestive Surg. 34, 151–160 (2016).
van Dijk, S. T. et al. A systematic review and meta-analysis of outpatient treatment for acute diverticulitis. Int. J. Colorectal Dis. 33, 505–512 (2018).
Cirocchi, R. et al. Is the outpatient management of acute diverticulitis safe and effective? A systematic review and meta-analysis. Tech. Coloproctol. 23, 87–100 (2019).
Shabanzadeh, D. M. & Wille-Jørgensen, P. Antibiotics for uncomplicated diverticulitis. Cochrane Database Syst. Rev. 11, CD009092 (2012).
Schug-Pass, C., Geers, P., Hügel, O., Lippert, H. & Köckerling, F. Prospective randomized trial comparing short-term antibiotic therapy versus standard therapy for acute uncomplicated sigmoid diverticulitis. Int. J. Colorectal Dis. 25, 751–759 (2010).
van de Wall, B. J. M. et al. Dietary restrictions for acute diverticulitis: evidence-based or expert opinion? Int. J. Colorectal Dis. 28, 1287–1293 (2013).
Stam, M. a. W. et al. An unrestricted diet for uncomplicated diverticulitis is safe: results of a prospective diverticulitis diet study. Colorectal Dis. 19, 372–377 (2017).
Rezapour, M. & Stollman, N. Antibiotics in uncomplicated acute diverticulitis: to give or not to give? Inflamm. Intest. Dis. 3, 75–79 (2018).
Chabok, A., Påhlman, L., Hjern, F., Haapaniemi, S. & Smedh, K. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br. J. Surg. 99, 532–539 (2012).
Daniels, L. et al. Randomized clinical trial of observationalversusantibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis. Br. J. Surg. 104, 52–61 (2016).
Emile, S. H., Elfeki, H., Sakr, A. & Shalaby, M. Management of acute uncomplicated diverticulitis without antibiotics: a systematic review, meta-analysis, and meta-regression of predictors of treatment failure. Tech. Coloproctol. 22, 499–509 (2018).
Mocanu, V. et al. The role of antibiotics in acute uncomplicated diverticulitis: a systematic review and meta-analysis. Am. J. Surg. 216, 604–609 (2018).
Au, S. & Aly, E. H. Treatment of uncomplicated acute diverticulitis without antibiotics: a systematic review and meta-analysis. Dis. Colon Rectum 62, 1533–1547 (2019).
Desai, M., Fathallah, J., Nutalapati, V. & Saligram, S. Antibiotics versus no antibiotics for acute uncomplicated diverticulitis: a systematic review and meta-analysis. Dis. Colon Rectum 62, 1005–1012 (2019).
Tandon, A., Fretwell, V. L., Nunes, Q. M. & Rooney, P. S. Antibiotics vs no antibiotics in the treatment of acute uncomplicated diverticulitis – a systematic review and meta-analysis. Colorectal Dis. 20, 179–188 (2018).
van Dijk, S. T. et al. Predictive factors on CT imaging for progression of uncomplicated into complicated acute diverticulitis. Int. J. Colorectal Dis. 32, 1693–1698 (2017).
Daniels, L. et al. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis. Br. J. Surg. 104, 52–61 (2017).
Sartelli, M. et al. WSES Guidelines for the management of acute left sided colonic diverticulitis in the emergency setting. World J. Emerg. Surg. 11, 37 (2016).
van Dijk, S. T. et al. Long-term effects of omitting antibiotics in uncomplicated acute diverticulitis. Am. J. Gastroenterol. 113, 1045–1052 (2018).
Stollman, N., Smalley, W., Hirano, I. & AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of acute diverticulitis. Gastroenterology 149, 1944–1949 (2015).
Evans, J. Does a 48-hour rule predict outcomes in patients with acute sigmoid diverticulitis? J. Gastrointest. Surg. 12, 577–582 (2008).
Gregersen, R., Mortensen, L. Q., Burcharth, J., Pommergaard, H.-C. & Rosenberg, J. Treatment of patients with acute colonic diverticulitis complicated by abscess formation: a systematic review. Int. J. Surg. 35, 201–208 (2016).
Gaertner, W. B. et al. Percutaneous drainage of colonic diverticular abscess: is colon resection necessary? Dis. Colon Rectum 56, 622–626 (2013).
Jalouta, T., Jrebi, N., Luchtefeld, M. & Ogilvie, J. W. Diverticulitis recurrence after percutaneous abscess drainage. Int. J. Colorectal Dis. 32, 1367–1373 (2017).
Lamb, M. N. & Kaiser, A. M. Elective resection versus observation after nonoperative management of complicated diverticulitis with abscess. Dis. Colon Rectum 57, 1430–1440 (2014).
Biondo, S. The diminishing role of surgery for acute diverticulitis. Br. J. Surg. 106, 308–309 (2019).
Halim, H., Askari, A., Nunn, R. & Hollingshead, J. Primary resection anastomosis versus Hartmann’s procedure in Hinchey III and IV diverticulitis. World J. Emerg. Surg. 14, 32 (2019).
Cirocchi, R. et al. Laparoscopic lavage versus surgical resection for acute diverticulitis with generalised peritonitis: a systematic review and meta-analysis. Tech. Coloproctol. 21, 93–110 (2017).
Penna, M., Markar, S. R., Mackenzie, H., Hompes, R. & Cunningham, C. Laparoscopic lavage versus primary resection for acute perforated diverticulitis. Ann. Surg. 267, 252–258 (2018).
Acuna, S. A. et al. Operative strategies for perforated diverticulitis: a systematic review and meta-analysis. Dis. Colon Rectum 61, 1442–1453 (2018).
Dindo, D., Demartines, N. & Clavien, P.-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240, 205–213 (2004).
Biondo, S., Lopez Borao, J., Millan, M., Kreisler, E. & Jaurrieta, E. Current status of the treatment of acute colonic diverticulitis: a systematic review. Colorectal Dis. 14, e1–e11 (2011).
Spiegel, B. M. R. et al. Development and validation of a disease-targeted quality of life instrument for chronic diverticular disease: the DV-QOL. Qual. Life Res. 24, 163–179 (2014). This is the first study that developed and validated a specific quality of life questionnaire for diverticular disease.
Hall, J. F. et al. Long-term follow-up after an initial episode of diverticulitis: what are the predictors of recurrence? Dis. Colon Rectum 54, 283–288 (2011).
Eglinton, T. et al. Patterns of recurrence in patients with acute diverticulitis. Br. J. Surg. 97, 952–957 (2010).
Cohen, E. et al. Increased risk for irritable bowel syndrome after acute diverticulitis. Clin. Gastroenterol. Hepatol. 11, 1614–1619 (2013).
Barbara, G. et al. Rome Foundation Working Team report on post-infection irritable bowel syndrome. Gastroenterology 156, 46–58.e7 (2019).
Dahl, C. et al. Evidence for dietary fibre modification in the recovery and prevention of reoccurrence of acute, uncomplicated diverticulitis: a systematic literature review. Nutrients 10, 137 (2018).
Khan, R. M. A., Ali, B., Hajibandeh, S. & Hajibandeh, S. Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. Colorectal Dis. 20, 469–478 (2018).
Stollman, N., Magowan, S., Shanahan, F. & Quigley, E. M. M., & DIVA Investigator Group. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J. Clin. Gastroenterol. 47, 621–629 (2013).
Nespoli, L. Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis. World J. Gastroenterol. 21, 8366–8372 (2015).
Lanas, A., Ponce, J., Bignamini, A. & Mearin, F. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study. Dig. Liver Dis. 45, 104–109 (2013).
Festa, V. et al. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. Eur. Rev. Med. Pharmacol. Sci. 21, 1397–1404 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03469050 (2019).
Tursi, A., Brandimarte, G. & Daffinà, R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig. Liver Dis. 34, 510–515 (2002).
Ünlü, Ç., Daniels, L., Vrouenraets, B. C. & Boermeester, M. A. Systematic review of medical therapy to prevent recurrent diverticulitis. Int. J. Colorectal Dis. 27, 1131–1136 (2012).
Aydin, H. N. & Remzi, F. H. Diverticulitis: when and how to operate? Dig. Liver Dis. 36, 435–445 (2004).
Janes, S., Meagher, A. & Frizelle, F. A. Elective surgery after acute diverticulitis. Br. J. Surg. 92, 133–142 (2005).
Collins, D. & Winter, D. C. Elective resection for diverticular disease: an evidence-based review. World J. Surg. 32, 2429–2433 (2008).
Regenbogen, S. E., Hardiman, K. M., Hendren, S. & Morris, A. M. Surgery for diverticulitis in the 21st century: a systematic review. JAMA Surg. 149, 292–303 (2014).
Strate, L. L., Peery, A. F. & Neumann, I. American Gastroenterological Association Institute Technical Review on the Management of Acute Diverticulitis. Gastroenterology 149, 1950–1976.e12 (2015).
van de Wall, B. J. M. et al. Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol. Hepatol. 2, 13–22 (2017).
Haas, J. M., Singh, M. & Vakil, N. Mortality and complications following surgery for diverticulitis: systematic review and meta-analysis. United European Gastroenterol. J. 4, 706–713 (2016).
Peppas, G., Bliziotis, I. A., Oikonomaki, D. & Falagas, M. E. Outcomes after medical and surgical treatment of diverticulitis: a systematic review of the available evidence. J. Gastroenterol. Hepatol. 22, 1360–1368 (2007).
Centers for Disease Control and Prevention. Health-related quality of life (HRQOL) (CDC, 2018).
Bolster, L. T. & Papagrigoriadis, S. Diverticular disease has an impact on quality of life – results of a preliminary study. Colorectal Dis. 5, 320–323 (2003).
McHorney, C. A., Ware, J. E. Jr, Rachel Lu, J. F. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care 32, 40–66 (1994).
van Dijk, S. T. et al. Quality of life and persistent symptoms after uncomplicated acute diverticulitis. Dis. Colon Rectum 62, 608–614 (2019).
EuroQol - A new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990).
Eypasch, E. et al. Gastrointestinal quality of life index: development, validation and application of a new instrument. Br. J. Surg. 82, 216–222 (1995).
Humes, D. J., Simpson, J., Neal, K. R., Scholefield, J. H. & Spiller, R. C. Psychological and colonic factors in painful diverticulosis. Br. J. Surg. 95, 195–198 (2007).
Tursi, A. et al. Impact of diverticular inflammation and complication assessment classification on the burden of medical therapies in preventing diverticular disease complications in Italy. Ann. Transl. Med. 5, 320–320 (2017).
Tursi, A. & Scarpignato, C. Symptomatic uncomplicated diverticular disease: chronic abdominal pain in diverticulosis is not enough to make the diagnosis. Clin. Gastroenterol. Hepatol. 16, 2001–2002 (2018).
Tursi, A. Diverticular disease of the colon and irritable bowel syndrome: it is time to differentiate. Am. J. Gastroenterol. 110, 774–775 (2015).
Biagi, E. et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 5, e10667 (2010).
Laghi, L. et al. Impact of treatments on fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon: a pilot study. J. Biol. Regul. Homeost. Agents 32, 1421–1432 (2018). This study demonstrated the influence of the current SUDD treatments on faecal microbiota and on urinary and faecal metabolome.
Ticinesi, A. et al. Diverticular disease: a gut microbiota perspective. J. Gastrointestin. Liver Dis. 28, 327–337 (2019).
Tursi, A. et al. Urinary metabolic profiling and symptomatic uncomplicated diverticular disease of the colon. Clin. Res. Hepatol. Gastroenterol. 41, 344–346 (2017).
Acknowledgements
The authors thank R. H. Hunt (McMaster University) for critical reading of the manuscript, useful discussions and suggestions, and G. A. Binda (Biomedical Institute, Genoa) for useful discussion and reviewing the section devoted to surgical management. L.L.S. acknowledges NIH funding for her research (R01DK101495 and R01DK103915).
Author information
Authors and Affiliations
Contributions
Introduction (A.T. and S.D.); Epidemiology (A. Lanas); Mechanisms/pathophysiology (L.L.S.); Diagnosis, screening and prevention (W.K.); Management (C.S.); Quality of life (A. Lahat); Outlook (A.T., C.S. and S.D.); Overview of Primer (A.T.). A.T. and C.S. contributed equally and are co-first authors.
Corresponding author
Ethics declarations
Competing interests
C.S. and A. Lanas are members of the Speakers’ Bureau and of the Scientific Advisory Board of Alfasigma SpA. W.K. served as speaker, consultant and/or advisory board member for Abbvie, Ardeypharm, Falk, Ferring, Genetic Analysis, Gräfe & Unze, Institut Allergosan, Nikkiso, Otsuka and Tillots. S.D. served as speaker, consultant, and/or advisory board member for Abbvie, Allergan, Alfa Wassermann, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead, Hospira, Johnson and Johnson, Merck, MSD, Mundipharma, Pfizer Inc., Sandoz, Takeda, Tigenix, UCB Pharma, Vifor. The remaining authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tursi, A., Scarpignato, C., Strate, L.L. et al. Colonic diverticular disease. Nat Rev Dis Primers 6, 20 (2020). https://doi.org/10.1038/s41572-020-0153-5
Accepted:
Published:
DOI: https://doi.org/10.1038/s41572-020-0153-5
This article is cited by
-
Gut microbiome structure and function in asymptomatic diverticulosis
Genome Medicine (2024)
-
Diagnostic delay in symptomatic uncomplicated diverticular disease: an Italian tertiary referral centre study
Internal and Emergency Medicine (2024)
-
Systematic review and meta-analysis of the management of acute uncomplicated diverticulitis: time to change traditional practice
International Journal of Colorectal Disease (2024)
-
Episodic Abdominal Pain—An Unexpected Cause for a Common Clinical Problem
Journal of General Internal Medicine (2024)
-
Evaluating frailty using the modified frailty index for colonic diverticular disease surgery: analysis of the national inpatient sample 2015–2019
Surgical Endoscopy (2024)